April 10, 2013, New York, NY - A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.
"With new immunotherapy agents available to help patients with melanoma, researchers are developing prognostic biomarkers to determine who will benefit most to fully realize the potential of these treatments," explained Jedd D. Wolchok, PhD, MD, director of Ludwig's Collaborative Laboratory at Memorial Sloan-Kettering Cancer Center during his presentations at AACR. "By identifying targeted combinations of agents, the immune response can be improved in certain patients with melanoma, the most dangerous form of skin cancer."
Developments in immunotherapeutic treatment of ovarian cancer was highlighted in a "Meet the Expert" session with George Coukos, PhD, MD, director of the Ludwig Center for Cancer Research of the University of Lausanne. His presentation educated on current progress and future prospects in vaccine and adoptive T-cell therapy development, as well as immunomodulatory therapy tools available for immediate clinical testing. "Ovarian cancer remains a very important therapeutic challenge," commented Dr. Coukos. "With no drugs approved in two decades in the U.S. and no therapeutic targets emerging from deep sequencing analyses, immunotherapy could offer a promising new approach."
Dr. Geoffrey Greene's team at the Ludwig Center at the University of Chicago analyzed epigenetic regulators called microRNAs - little pieces of ribonucleic acid that are present in all the cells in the body - to better understand treatment challenges of metastasis and chemotherapy resistance in patients with triple negative breast cancer.
"Our research used a novel human tumor xenograft model to better understand the fundamental mechanisms of these tumors," said lead author Huiping Liu, Research Associate, Ben May Department and the Ludwig Center, University of Chicago. "We know that proteins turn genes on and off but so do microRNAs. Our team discovered a small yet influential microRNA known as 30c. When it is present in cells it inhibits metastasis and improves a patient's response to chemotherapy treatment. Our findings may provide a potential new treatment target for this difficult to treat cancer."
From Dr. Bing Ren's laboratory of gene regulation at the Ludwig Institute for Cancer Research in San Diego, post-doctoral fellow Gary Hon, PhD described how adult tissues retain an epigenetic memory of their past development. Further, Dr. Ren shared research related to long-range control of gene expression in mammalian cells during an educational session.
Click here for a complete schedule of presentations from Ludwig scientists.
About the Ludwig Institute for Cancer Research
The Ludwig Institute is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has spent more than $1.5 billion on cancer research. http://www.
For further information please contact Rachel Steinhardt, firstname.lastname@example.org or +1-212-450-1582.